Confo Therapeutics

Today we are thrilled to announce the close of our €60 million Series B financing round led by Ackermans & van Haaren. We also welcome our other new investors, Driehaus Capital Management LLC and Quest for Growth, as they participate with our existing investors in this funding round.   The funds will advance our metabolic and rare endocrine disease programs including 2 through Phase 1, and 2 to IND approval. We thank our international investors for their support and look forward to accelerating our ambitious development pipeline.   Read more about the announcement here: https://lnkd.in/eha9QXFz

Today Confo announced that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant will be used to expand Confo’s ongoing R&D efforts using its patent-protected technology platform for the discovery of next-generation medicines targeting Class B GPCRs for the treatment of a range of endocrine and metabolic diseases including obesity. Access the full press release at: https://lnkd.in/eSyCJRps

We are delighted to share that our CEO, Cedric Ververken was awarded the “Private Company CEO of the Year” title at the 2023 European Lifestars Awards earlier this week in London. This award recognises Cedric’s leadership and the hard work of the entire Confo team resulting in multiple impactful deals in 2023. Confo was also voted 2nd place for the “Deal of the Year >€500M” category, recognizing our global licensing agreement with Eli Lilly and Company for CFTX-1554, our clinical-stage candidate for the treatment of peripheral pain. Congratulations to all winners! Additional details can be found at https://lnkd.in/eA_kB9-J   #lifestarawards #biotech #lifesciences

Thrilled to announce that our transformative deal with Eli Lilly and Company for CFTX-1554, our clinical-stage peripheral pain candidate, has been nominated for the ‘Deal of the year (>€500 million)’ award at the European Lifestars Awards. We're looking forward to attending the awards gala on 13th November in London! Link to Lifestars awards: https://lnkd.in/g-k5fms More information on the deal: https://lnkd.in/edb4__Ur #lifestarsawards #biotech #lifesciences

Great to have you on board Steve!

We are thrilled to announce the appointment of Stephen Dowd, PhD, MBA, as our Chief Business Officer (CBO) effective September 12, 2023. Stephen’s 25 years of experience working in biotechnology and pharmaceutical companies will be a valuable asset as we continue to advance our promising pipeline and maximize the value of our proprietary discovery platform. We look forward to welcoming Stephen to our Executive Team and to working together towards our goal of addressing a broader array of critical unmet medical needs. For more information on this announcement, please find our press release here: https://lnkd.in/eSYnxwfe